Physician profile
Daniel Har
NPI 1811330392
$12,565.22
in general payments reported to CMS, 2019-2025
44 companies · $2,751 in 2025
The $2,751 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $1,243 · 2021: $1,390 · 2022: $1,918 · 2023: $1,898 · 2024: $2,085 · 2025: $2,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,403 · Honoraria: $175 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,403.32 |
| Honoraria | $175.00 |
| Education | $156.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,690.81 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,423.90 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,287.99 | 2019-2025 | Dupixent |
| Genzyme Corporation | $917.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $750.64 | 2020-2025 | |
| Grifols USA, LLC | $365.00 | 2020-2025 | Xembify |
| Covis Pharma Gmbh | $344.91 | 2020-2023 | |
| Pfizer INC. | $341.57 | 2019-2025 | |
| Kaleo, INC. | $331.71 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $331.15 | 2020-2025 | Takhzyro, Cuvitru |
| Galderma Laboratories, L.P. | $317.16 | 2024-2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $315.87 | 2022-2024 | |
| Genentech USA, INC. | $307.99 | 2019-2025 | Xolair, Tecentriq |
| Amgen INC. | $268.34 | 2022-2025 | Tezspire |
| Abbvie INC. | $265.50 | 2022-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $216.73 | 2019-2022 | |
| Optinose US, INC. | $191.75 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.65 | 2019-2022 | |
| Alk-Abello, INC | $175.74 | 2019-2025 | Timothy, Standardized, Standardized Mite D. Farinae, Histamine Positive |
| Teva Pharmaceuticals USA, INC. | $150.77 | 2020-2023 | |
| Hikma Pharmaceuticals USA | $143.21 | 2023-2024 | Ryaltris |
| Leo Pharma INC. | $136.04 | 2025 | Adbry, Anzupgo |
| Shire North American Group INC | $130.89 | 2019 | |
| Organon LLC | $110.74 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $97.23 | 2025 | Neffy |
| Pharming Healthcare, INC. | $95.89 | 2021-2025 | Ruconest |
| Lilly USA, LLC | $60.90 | 2024-2025 | Ebglyss |
| Incyte Corporation | $53.90 | 2021-2025 | Opzelura |
| Blueprint Medicines Corporation | $52.75 | 2023-2024 | Ayvakit |
| Greer Laboratories, INC. | $51.09 | 2024 | Palforzia |
| Phadia US INC. | $50.32 | 2022-2024 | Immunocap |
| Regeneron Pharmaceuticals, INC. | $44.06 | 2023-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $42.63 | 2021-2023 | |
| Circassia INC. | $32.95 | 2019 | |
| Csl Behring | $31.49 | 2024 | Hizentra, Privigen |
| Aytu Biopharma, INC. | $28.73 | 2020-2024 | Karbinal |
| Gc Biopharma USA, INC. | $23.47 | 2024 | Alyglo |
| Uswm, LLC | $20.17 | 2021 | |
| Biocryst US Sales Co., LLC | $19.74 | 2024 | Orladeyo |
| Neos Therapeutics, LP | $17.86 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.97 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.77 | 2025 | Zoryve |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Har listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.